Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
TuHURA Biosciences ( (HURA) ) has provided an announcement.
On December 9, 2025, TuHURA Biosciences announced a securities purchase agreement with investors for a registered direct offering of 9,462,423 shares of common stock and accompanying warrants, expected to raise approximately $15.6 million in three tranches. The proceeds will be used for working capital, satisfying a $3.4 million bridge note obligation, and general corporate purposes, impacting the company’s financial operations and potentially strengthening its market position.
The most recent analyst rating on (HURA) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel therapeutics to overcome resistance to cancer immunotherapy. The company is working on products like IFx-2.0, an innate immune agonist designed to address primary resistance to checkpoint inhibitors, and TBS-2025, a VISTA inhibiting mAb for AML. TuHURA is also leveraging Delta Opioid Receptor technology to develop bi-specific antibody drug conjugates targeting immune-suppressing cells.
Average Trading Volume: 237,168
Technical Sentiment Signal: Sell
Current Market Cap: $101.5M
Find detailed analytics on HURA stock on TipRanks’ Stock Analysis page.